阅读说明：本技术 基于松油醇的杀菌组合物 (Terpineol-based bactericidal composition ) 是由 王礼文 刘鹏 陈佛祥 张志伟 朱刚 董奇 于 2020-12-28 设计创作，主要内容包括：本发明公开了一种基于松油醇杀菌组合物,活性成分为苯丙烯菌酮和左旋α-松油醇,苯丙烯菌酮和左旋α-松油醇的质量份数比例为7:1～1:15,优选比例为3:1～1:10；苯丙烯菌酮与左旋α-松油醇在组合物中的质量百分含量为0.1％～50％,其余为助剂。组合物对植物病原真菌具有协同作用,尤其是黄瓜靶斑病。(The invention discloses a terpineol-based bactericidal composition, which comprises active ingredients of hydrocinnamone and levorotatory alpha-terpineol, wherein the mass part ratio of the hydrocinnamone to the levorotatory alpha-terpineol is 7: 1-1: 15, and the preferable ratio is 3: 1-1: 10; the mass percentage of the hydrocinnamone and the levorotatory alpha-terpineol in the composition is 0.1 to 50 percent, and the balance is the auxiliary agent. The composition has synergistic effect on plant pathogenic fungi, especially cucumber target spot.)

1. A terpineol-based bactericidal composition is characterized in that: the active ingredients are the phenylalkenones and the terpineol, or the active ingredients are the phenylalkenones and the levorotatory alpha-terpineol.

2. The germicidal composition of claim 1, wherein: when the active ingredients are the phenylalkenones and the levorotatory alpha-terpineol, the mass part ratio of the phenylalkenones to the levorotatory alpha-terpineol is 7: 1-1: 15.

3. The germicidal composition of claim 2, wherein: the mass part ratio of the hydrocinnamone to the levorotatory alpha-terpineol is 3: 1-1: 10.

4. The germicidal composition of claim 2, wherein: the mass part ratio of the phenylalkenones to the levorotatory alpha-terpineol is 1: 6.

5. The bactericidal composition according to any one of claims 1 to 4, wherein: the bactericidal composition also contains other active ingredients, so that the control range is expanded and the control effect is improved.

6. The bactericidal composition according to any one of claims 1 to 4, wherein: the bactericidal composition also contains other inactive ingredients for assisting the action.

7. The germicidal composition according to any of claims 1-4, characterized in that: the bactericidal composition is processed into microemulsion.

8. Use of the fungicidal composition according to any one of claims 1 to 4 for controlling diseases caused by plant pathogens.

9. The use of the fungicidal composition according to claim 8 for controlling diseases caused by plant pathogens, characterized in that: the plant disease is cucumber target spot.

Technical Field

The invention belongs to the field of pesticide synergistic compositions, and particularly relates to a bactericidal composition with active ingredients of fenacet and levorotatory alpha-terpineol.

Background

Hydrocinnamophenone, common english name: isobavachalcone, chemical name: (E) -1- [2, 4-dihydroxy-3- (3-methyl-butyl-2-alkenyl) phenyl ] -3- (4-hydroxyphenyl) propen-2-one-1, the hydrocinnamone is a broad spectrum bactericide of plant origin, and the extraction source is seed of Psoralea corylifolia of leguminosae. The seed extract has the functions of killing or inhibiting growth and propagation of various pathogenic bacteria harmful to crops to different degrees, and especially has obvious effect of preventing and treating important plant diseases such as cucumber target spot, rice blast, apple canker, early and late blight, anthracnose and the like. The action mechanism is that the aim of sterilization is achieved by destroying wall membrane systems of pathogenic bacteria such as cell walls, cell membranes, mitochondrial membranes, nuclear membranes and the like and interfering the cell metabolic process. Low toxicity to human and livestock, no hidden danger of residue to environmental safety, and is especially suitable for green and organic agricultural production.

Terpineol is also called Terpineol and has alpha, beta and gamma 3 isomers, wherein the levorotatory alpha-Terpineol is the most common in nature, and the levorotatory alpha-Terpineol (English common name alpha- (L) -Terpineol) (see Chinese patent, patent number: ZL 03178548.4) has good bactericidal activity and better deodorization, wetting and permeability, and can be used as an agricultural bactericide.

CN201010525127.7 discloses a bactericide composition containing propiconazole, flusilazole and levorotatory alpha-terpineol and a production method thereof, which can be used for preventing and treating banana leaf spot disease, banana scab, pear scab, peanut leaf spot disease, apple anthracnose and grape anthracnose.

CN200910114473.3 discloses a bactericide composition containing difenoconazole and levorotatory alpha-terpineol, which is used for preventing and treating sigatoka.

CN201210361858.1 discloses an isopsoralen chalcone soluble liquid used for preventing and treating plant fungal diseases such as rice blast, apple canker and the like. CN201811311692.6 discloses that the mixture of fructus Psoraleae extract and antibiotics, amides, triazoles, etc. can enhance the control effect, and can treat multiple diseases simultaneously in the growth period of crops in one-time application, so that multiple repetitive field operations can be completed at one time, the labor force is saved, and the cost is reduced.

The price of developing a new product of bactericide is high, the period is long, and compared with the price of developing and researching a high-efficiency, low-toxicity and low-residue compound and mixture, the investment is small, the development period is short, the attention at home and abroad is paid to the development, and the development strength is increased at a large margin.

The combination of fenapanol and levo alpha-terpineol has not been reported.

Disclosure of Invention

The invention discloses a bactericidal composition for preventing and treating crop diseases, in particular to target spot of cucumber.

The invention is realized by the following technical scheme:

the active ingredients of the bactericidal composition are the phenylalkenones and the terpineol, preferably the phenylalkenones and the levorotatory alpha-terpineol, and the mass part ratio of the phenylalkenones to the levorotatory alpha-terpineol is 7: 1-1: 15, preferably 3: 1-1: 10, and further preferably 1: 6.

The mass percentage of the hydrocinnamone and the levorotatory alpha-terpineol in the composition is 0.1 to 50 percent, and the balance is the auxiliary agent.

The bactericide composition is added with an auxiliary agent and an excipient and prepared into agriculturally commonly used dosage forms such as microemulsion and the like by a certain technical means.

The microemulsion product comprises 0.01-1 wt% of hydrocinnamone, 0.01-50 wt% of levorotatory alpha-terpineol, 0.1-2 wt% of a dispersant, 0.1-1 wt% of an antifreeze, 0.1-3 wt% of a solvent, 0.1-5 wt% of an emulsifier and purified water which is supplemented to 100 wt%. Mixing the above raw materials uniformly, and slowly adding the rest purified water under stirring at normal temperature to obtain homogeneous transparent microemulsion.

The antifreezing agent can be one or more of glycerol, propylene glycol, diethylene glycol, urea and the like.

The dispersing agent can be one or more of isomeric alcohol polyoxyethylene ether, polycarboxylate, alkylphenol polyoxyethylene ether sulfate, fatty acid ester sulfate, alkylphenol polyoxyethylene ether, fatty alcohol polyoxyethylene ether, polyethylene glycol stearate, sorbitol oleate, polyoxyethylene polyoxypropylene ether block polymer and the like.

The emulsifier can be agricultural milk 33#, agricultural milk 34#, agricultural milk 500#, agricultural milk 600#, agricultural milk 700#, agricultural milk 1601#, agricultural milk 1602#, T60, S80, TX-10, OP-10, NP-10 and triphenylethyl phenol polyoxyethylene ether phosphate.

The solvent can be mineral spirit S-150, mineral spirit S-200, ethanol, isopropanol, n-butanol, n-octanol, n-pentanol, cyclohexanone, hexane, dimethylformamide, ethyl acetate, methyl oleate, dibutyl phthalate, sec-butyl acetate and isomeric alcohol.

The water is deionized water.

The composition of the invention can also be mixed with other pesticides to improve the control effect or expand the control spectrum or have synergistic effect on targets, and the compounds can be:

(1) inhibitors of ergosterol synthesis (1.1) aldimorph (1704-28-5), (1.2) azaconazole (60207-31-0), (1.3) chlorofluoromethane, (1.4) bromuconazole (116255-48-2), (1.5) cyproconazole (113096-99-4), (1.6) diclosonazole (75736-33-3), (1.7) difenoconazole (119446-68-3), (1.8) diniconazole (83657-24-3), (1.9) diniconazole-M (diniconazole-M) (83657-18-5), (1.10) dodecamorph (3-77-7), (1.11) dinoconazole (310-11) (310-106325), (1.3) azazole (3138-3), (1.13) epoxiconazole (etaconazole) (60207-93-4), (1.14) isopimanol (fenarimol) (60168-88-9), (1.15) fenbuconazole (fenbuconazole) (114369-43-6), (1.16) fenhexamid (126833-17-8), (1.17) fenpropidin (fenpropidin) (67306-00-7), (1.18) fenpropimorph (fenpropimorph) (67306-03-0), (1.19) fluquinconazole (fluquinconazole) (136426-54-5), (1.20) flurprimol (flurprimidone) (56425-91-3), (1.21) flusilazole (fluquinconazole) (85509-19-9), (1.22) flutriafol (63-21) (6723-3), (1.21) flusilazole (fenpropiconazole) (6723-3), (1.3) fluquinconazole (3625-3), (3.3) fluquinconazole (fenpropiconazole) (6723-3), (3.21) fluquinconazole (fluquinconazole) (3623-3), (1.25) hexaconazole (79983-71-4), (1.26) imazalil (60534-80-7), (1.27) imazalil sulfate (58594-72-2), (1.28) imibenconazole (86598-92-7), (1.29) ipconazole (125225-28-7), (1.30) metconazole (125116-23-6), (1.31) myclobutanil (88671-89-0), (1.32) naftifine (65472-88-0), (1.33) nuarimol (63284-71-9), (1.34) imidazole (oxoponazole) (174212-12-5), (1.35) fenbuconazole (101903-764), (1.35) fenbuconazole (101903-9), (1.32-71-9), (1.34) imidazole (oxopuconazole (174212-12-5), (1.35-35) fenbuconazole (539-2-764) (764-6-2-6), (1.37) penconazole (penconazole) (66246-88-6), (1.38) proparazolin (pipalin) (3478-94-2), (1.39) prochloraz (prochloraz) (67747-09-5), (1.40) propiconazole (propiconazole) (60207-90-1), (1.41) prothioconazole (prothioconazole) (178928-70-6), (1.42) pyributicarb (pyributicarb) (88678-67-5), (1.43) pyribenzoxim (pyrifenox) (88283-41-4) (1.44) azoloquinazolinone (quinconazole) (103970-75-8), (1.45) simeconazole (simeconazole) (149508-90-7), (1.46) spiroxamine (7-30-8) (351.45) tebuconazole (3648-3548) (3548-1.48-3548) (3648-3548-1.48) propiconazole (propiconazole) (60248-1.8) (3648-3548) and (3-5634-3) propiconazole (proparazoline (naproxobin) (6021.6), (1.50) triazolone (triadimifone) (43121-43-3), (1.51) triadimenol (triadiminol) (89482-17-7), (1.52) tridemorph (tridemorph) (81412-43-3), (1.53) triflumizole (68694-11-1), (1.54) triforine (triforine) (26644-46-2), (1.55) triticonazole (triticonazole) (131983-72-7), (1.56) uniconazole (83657-22-1), (1.57) uniconazole (83657-17-4), (1.58) dimethomozole (77174-66-4), (1.59) voriconazole (137234-62-9), (1.60) chlorphenyl (1-4-1-2-4, 1.9) cycloheptanol (129586-1-32-1, 2-4, 1.9) troconazole (1.4), (1.61) methyl 1- (2, 2-dimethyl-2, 3-dihydro-1H-inden-1-yl) -1H-imidazole-5-carboxylate (110323-95-0), (1.62) N '- {5- (difluoromethyl) -2-methyl-4- [3- (trimethylsilyl) propoxy ] phenyl } -N-ethyl-N-methyliminocarboxamide, (1.63) N-ethyl-N-methyl-N' - { 2-methyl-5- (trifluoromethyl) -4- [3- (trimethylsilyl) propoxy ] phenyl } iminocarboxamide, and (1.64) O- {1- [ (4-methoxyphenoxy) -3, 3-dimethylbut-2-yl } -1H-imidazole-1-thiocarbonate (111226-71-2).

(2) Inhibitors of respiratory chain complex I or II, such as (2.1) bixafen (581809-46-03), (2.2) boscalid (boscalid) (188425-85-6), (2.3) carboxin (5234-68-4), (2.4) diflumetorim (diflumetorim) (130339-07-0), (2.5) methylfuroamide (fenfuram) (24691-80-3), (2.6) fluopyram (flupyrad) (658066-35-4), (2.7) fluindazofamide, (2.8) fluxapyrod (907204-31-3), (2.9) furametpyr (123572-88-3), (2.10) furametpyr (60568-05-0), (2.11) naphthopyrad (isopyram, cis-epimeric racemate and trans-epimeric racemate RS, RS-1-4, 4SR,9SR mixture) (88165-58-1), (2.12) naphthyridine (isopyrazam, trans-epimeric racemate 1RS,4SR,9SR), (2.13) naphthyridine (isopyrazam, trans-epimeric enantiomer 1R,4S,9S), (2.14) naphthyridine (isopyrazam, trans-epimeric enantiomer 1S,4R,9R), (2.15) naphthyridine (isopyrazam, cis-epimeric racemate 1RS,4SR,9RS), (2.16) naphthyridine (isopyrazam, cis-epimeric enantiomer 1R,4S,9R), (2.17) naphthyridine (isopyrazam, cis-epimeric enantiomer 1S,4R,9S), (2.18) fenpyrazamine (isopyrazam, cis-epimeric enantiomer 1S,4R,9R), (2.17) fenpyrazam (55814) (3519-19) oxazarin 5259-19) (2.19-oxazam), (2.20) penflufen (penflufen) (494793-67-8), (2.21) penthiopyrad (penthiopyrad) (183675-82-3), (2.22) cyprodinil (sedaxane) (874967-67-6), (2.23) flufenacet (thifluzamide) (130000-40-7), (2.24) 1-methyl-N- [2- (1,1,2, 2-tetrafluoroethoxy) phenyl ] -3- (trifluoromethyl) -1H-pyrazole-4-carboxamide, (2.25)3- (difluoromethyl) -1-methyl-N- [2- (1,1,2, 2-tetrafluoroethoxy) phenyl ] -1H-pyrazole-4-carboxamide, (2.26)3- (difluoromethyl) -N- [ 4-fluoro-2- (1,1,2,3,3, 3-hexafluoropropoxy) phenyl ] -1-methyl-1H-pyrazole-4-carboxamide, (2.27) N- [1- (2, 4-dichlorophenyl) -1-methoxypropan-2-yl ] -3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxamide (1092400-95-7) (WO2008148570), (2.28)5, 8-difluoro-N- [2- (2-fluoro-4- { [4- (trifluoromethyl) pyridin-2-yl ] oxy } phenyl) ethyl ] quinazolin-4-amine (1210070-84-0) (WO2010025451), (2.29) N- [9- (dichloromethylene) -1,2,3, 4-tetrahydro-1, 4-methylenenaphthalen-5-yl ] -3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxamide, (2.30) N- [ (1S,4R) -9- (dichloromethylene) -1,2,3, 4-tetrahydro-1, 4-methylenenaphthalen-5-yl ] -3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxamide and (2.31) N- [ (1R,4S) -9- (dichloromethylene) -1,2,3, 4-tetrahydro-1, 4-methylenenaphthalen-5-yl ] -3- (difluoromethyl) -1-methyl-1H-pyrazole-4- Formamide.

(3) Inhibitors of respiratory chain complex III such as (3.1) ametoctradin (865318-97-4), (3.2) amisulbactam (amisulbactam) (348635-87-0), (3.3) azoxystrobin (azoxystrobin) (131860-33-8), (3.4) cyazofamid (120116-88-3), (3.5) coumoxystrobin (850881-30-0), (3.6) coumoxystrobin (850881-70-8), (3.7) dimoxystrobin (141600-52-4), (3.8) enamelphenicol (strostrobin) (1617-11-2) (WO2004/058723), (3.9) famoxadone (131807-57-3) (2004/058723), (WO 3.10) imidazolone (1617-11-2) (WO2004/058723), (WO 2004-3.9) famoxadone (16131-3523) (WO 3527-326-9/058723) (WO 19/05873/0519) fluoxastrobin (3623) (WO 19/05873/0519) (WO 3/0519) fluxastrobin (3623), (3.13) kresoxim-methyl (kresoxim-methyl) (143390-89-0) (WO2004/058723), (3.14) metominostrobin (133408-50-1) (WO2004/058723), (3.15) orysastrobin (orysastrobin) (189892-69-1) (WO2004/058723), (3.16) picoxystrobin (picoxystrobin) (117428-22-5) (WO2004/058723), (3.17) pyraclostrobin (pyraclostrobin) (175013-18-0) (WO2004/058723), (3.18) picoxystrobin (915410-70-7) (WO2004/058723), (3.19) pyraoxystrobin (862588-11-2) (WO2004/058723), (3.20) pyraclostrobin (799247-862) (WO 2004-05873.3-3- { [ 3.3.3.3-3) and 3.3.3.3.3.5) pyraclostrobin (pyraclostrobin) (WO 2004-3 -fluoropyrimidin-4-yl ] oxy } phenyl) -2- (methoxyimino) -N-methylacetamide (WO2004/058723), (3.24) (2E) -2- (methoxyimino) -N-methyl-2- (2- { [ ({ (1E) -1- [3- (trifluoromethyl) phenyl ] ethylidene } amino) oxy ] methyl } phenyl) acetamide (WO2004/058723), (3.25) (2E) -2- (methoxyimino) -N-methyl-2- {2- [ (E) - ({1- [3- (trifluoromethyl) phenyl ] ethoxy } imino) methyl ] phenyl } acetamide (158169-73-4), (3.26) (2E) -2- {2- [ ({ [ (1E) -1- (3- (trifluoromethyl) phenyl ] ethoxy } imino) methyl ] phenyl } acetamide (158169-73-4) - { [ (E) -1-fluoro-2-phenylethenyl ] oxy } phenyl) ethylidene ] amino } oxy) methyl ] phenyl } -2- (methoxyimino) -N-methylacetamide (326896-28-0), (3.27) (2E) -2- {2- [ ({ [ (2E,3E) -4- (2, 6-dichlorophenyl) but-3-en-2-ylidene ] amino } oxy) methyl ] phenyl } -2- (methoxyimino) -N-methylacetamide, (3.28) 2-chloro-N- (1,1, 3-trimethyl-2, 3-dihydro-1H-inden-4-yl) pyridine-3-carboxamide (119899-14-8), (3.29) methyl 5-methoxy-2-methyl-4- (2- { [ ({ (1E) -1- [3- (trifluoromethyl) phenyl ] ethylidene } amino) oxy ] methyl } phenyl) -2, 4-dihydro-3H-1, 2, 4-triazol-3-one, (3.30) (2E) -2- {2- [ ({ cyclopropyl [ (4-methoxyphenyl) imino ] methyl } thio) methyl ] phenyl } -3-methoxyprop-2-enoate (149601-03-6), (3.31) N- (3-ethyl-3, 5, 5-trimethylcyclohexyl) -3- (carboxamido) -2-hydroxybenzamide (226551-21-9), (3.32)2- {2- [ (2, 5-dimethylphenoxy) methyl ] phenyl } -2-methoxy-N-methylacetamide (173662-97-0) and (3.33) (2R) -2- {2- [ (2, 5-dimethylphenoxy) methyl ] phenyl } -2-methoxy-N-methylacetamide (394657-24-0).

(4) Mitosis and cell division inhibitors such as (4.1) benomyl (benomyl) (17804-35-2), (4.2) carbendazim (carbendazim) (10605-21-7), (4.3) benzimidazole (chlorofenazole) (3574-96-7), (4.4) diethofencarb (diethofencarb) (87130-20-9), (4.5) omethoam (ethaxam) (162650-77-3), (4.6) fluopicolide (fluopicolide) (239110-15-7), (4.7) fuberidazole (fuberidazole) (3878-19-1), (4.8) pencycuron (66063-05-6), (4.9) thiabendazole (thiabendazole) (148-79-8), (4.10) thiophanate (thiophanate-32-68) (364.11-36-32-36) (364.4.9) thiophanate (thiophanate-32-9) (364.4.4.4-6), (4.13) 5-chloro-7- (4-methylpiperidin-1-yl) -6- (2,4, 6-trifluorophenyl) [1,2,4] triazolo [1,5-a ] pyrimidine (214706-53-3) and 3-chloro-5- (6-chloropyridin-3-yl) -6-methyl-4- (2,4, 6-trifluorophenyl) pyridazine (1002756-87-7).

(5) Examples of the compound having a multidentate effect include (5.1) Bordeaux mixture (8011-63-0), (5.2) captafol (2425-06-1), (5.3) captan (captan) (133-06-2) (WO02/12172), (5.4) chlorothalonil (1897-45-6), (5.5) copper hydroxide (20427-59-2), (5.6) copper naphthenate (1338-02-9), (5.7) copper oxide (1317-39-1), (5.8) copper oxychloride (1332-40-7), (5.9) copper sulfate (7758-98-7), (5.10) dichlofluanid (1085-98-9), (5.11) dithianon (3347-22-6), (5.10) dodine (2447-6-12) (39-10) (243-10), (5.13) dodine free base (dodin free base), (5.14) ferbam (14484-64-1), (5.15) fluoropress (719-96-0), (5.16) folpet (133-07-3), (5.17) iminoctadine (guazatine) (108173-90-6), (5.18) iminoctadine (guazatine acetate), (5.19) iminoctadine (13516-27-3), (5.20) iminoctadine (iminoctadine), 169202-06-6), (5.21) iminoctadine acetate (57520-17-9), (5.22) manganin (53988-93-5), (5.23) iminoctadine (8018-9), (5.8) iminoctadine (9005-368-12427), (365.8-368-12427) iminoctadine (368-3), (5.26) zineb (metiram zinc) (9006-42-2), (5.27) zinc thiazole, (5.28) propamide (104-32-5), (5.29) propineb (propineb) (12071-83-9), (5.30) sulfur and sulfur formulations including calcium polysulfide (7704-34-9), (5.31) thiram (thiram) (137-26-8), (5.32) tolylfluanid (tolyfluanid) (731-27-1), (5.33) zinc metiram (zineb) (12122-67-7) and (5.34) zinc metiram (137-30-4).

(6) Compounds capable of inducing host defense such as (6.1) benzothiadiazole (acibenzolar-S-methyl) (135158-54-2), (6.2) isotianil (isotianil) (224049-04-1), (6.3) probenazole (27605-76-1) and (6.3) tiadinil (tiadinil) (223580-51-6).

(7) Amino acid and/or protein biosynthesis inhibitors such as (7.1) amphetamine (andoprim) (23951-85-1), (7.2) blasticidin (blestic-S) (2079-00-7), (7.3) cyprodinil (121552-61-2), (7.4) kasugamycin (kasugamycin) (6983), (7.5) kasugamycin hydrochloride hydrate (kasugamycin hydrochloride) (19408-46-9), (7.6) mepanipyrim (110235-47-7), (7.7) pyrimethanil (pyrimethanil) (53112-28-0) and 3- (5-fluoro-3, 3,4, 4-tetramethyl-3, 4-dihydroisoquinolin-1-yl) quinoline (861647-32-7) (WO 20070917).

(8) ATP production inhibitors (8.1) triphenyltin acetate (fentin acetate) (900-95-8), (8.2) fentin chloride (fentin chloride) (639-58-7), (8.3) fentin hydroxide (76-87-9) and (8.4) silthiopham (175217-20-6).

(9) Cell wall synthesis inhibitors such as (9.1) benthiavalicarb (benthiavalicarb) (177406-68-7), (9.2) dimethomorph (110488-70-5), (9.3) flumorph (flumorph) (211867-47-9), (9.4) iprovalicarb (140923-17-7), (9.5) mandipropamid (374726-62-2), (9.6) polyoxins (11113-80-7), (9.7) polyoxins (polyoxomim) (22976-86-9), (9.8) validamycin A (validamycin A) (37248-47-8) and (9.9) valinalate (283159-94-4; 283159-90-0).

(10) Lipid and membrane synthesis inhibitors such as (10.1) biphenyl (biphenyl) (92-52-4), (10.2) dicyclopentadine (chloroneb) (2675-77-6), (10.3) niclosamide (dicloran) (99-30-9), (10.4) edifenphos (edifenphos) (17109-49-8), (10.5) etridiazole (ethiodiazole) (2593-15-9), (10.6) iodocarb (55406-53-6), (10.7) iprobenfos (26087-47-8), (10.8) isoprothiolane (isoprothiolane) (50512-35-1), (10.9) propamocarb (propamocarb) (25606-41-1), (10.10) propamocarb hydrochloride (propamocarb) (196606-41-1), (25606.10) propamocarb (propamocarb) (19641-1) (10.11) thiocarb) (10.11-18) (thiocarb) (10.11) thiocarb (propamocarb) (10.11-18-2), (10.13) Pentachloronitrobenzene (quintozene) (82-68-8), (10.14) Tetrachloronitrobenzene (tecnazene) (117-18-0) and (10.15) Methylphosphine (tolclofos-methyl) (57018-04-9).

(11) Melanin biosynthesis inhibitors such as (11.1) carpropamide (carpropamid) (104030-54-8), (11.2) cyanamide (diclocymet) (139920-32-4), (11.3) fenoxanil (115852-48-7), (11.4) tetrachlorophthalide (phthalid) (27355-22-2), (11.5) pyroquilon (pyroquilon) (57369-32-1), (11.6) tricyclazole (41814-78-2) and (11.7) { 3-methyl-1- [ (4-methylbenzoyl) amino ] butan-2-yl } carbamic acid 2,2, 2-trifluoroethyl ester (851524-22-6) (WO 2005042474).

(12) Nucleic acid synthesis inhibitors such as (12.1) benalaxyl (benalaxyl) (71626-11-4), (12.2) benalaxyl-M, kiralaxyl) (98243-83-5), (12.3) bupirimate (41483-43-6), (12.4) clozylacon (67932-85-8), (12.5) dimethirimol (5221-53-4), (12.6) ethirimol (ethirimol) (23947-60-6), (12.7) furalaxyl (furalaxyl) (57646-30-7), (12.8) hymexazol (10004-44-1), (12.9) metalaxyl (57837-19-1), (12.10) metalaxyl (M-36-11-12) (3648.11) and (7712.12) methoxazolone (36-12.11-7712) (36-12.11-7712.13) furoxan (36-12.11-12) furoxanol (3648-12.6) and (36-7712.6) furoxan (furoxan) (57646-7) furoxyl (57646-7) 14698-29-4).

(13) Signal transduction inhibitors such as (13.1) ethiprole (chlorozolinate) (84332-86-5), (13.2) fenpiclonil (74738-17-3), (13.3) fluoroxas (fluoroxonil) (131341-86-1), (13.4) iprodione (36734-19-7), (13.5) procymidone (32809-16-8), (13.6) quinoxyfen (quinoxyfen) (124495-18-7) and (13.7) enaminone (vinclozolin) (50471-44-8).

(14) Compounds capable of acting as uncouplers, for example, (14.1) binapacryl (485-31-4), (14.2) dinocap (131-72-6), (14.3) pyrimethanzone (ferimzone) (89269-64-7), (14.4) fluazinam (79622-59-6) and (14.5) meptyldinocap (131-72-6).

(15) Other compounds, for example, (15.1) benthiavalicarb (benthiazole) (21564-17-0), (15.2) betaxazin (163269-30-5), (15.3) carbapenem (capsomycin) (70694-08-5), (15.4) carvone (carvone) (99-49-0), (15.5) cimetidine (chinomethionat) (2439-01-2), (15.6) pyriofenone (chlazonone) (688046-61-9), (15.7) thiabendazole (cufraneb) (11096-18-7), (15.8) cyflufenamid (180409-60-3), (15.9) cymoxanil (57966-95-7), (15.10) cyprosulfamide (cyprosulfamide) (5-31-533), (15.9) cymoxanil (cyflufenamide) (3876-31-12) (15.11-12) and (carbamazepine) (15.6-12) carbaryl (carbamazepine) (15.6-12), (15.13) dichlorophenol (dichlorophen) (97-23-4), (15.14) pyridaben (diclomezine) (62865-36-5), (15.15) difenzoquat (49866-87-7), (15.16) difenzoquat methyl sulfate (43222-48-6), (15.17) diphenylamine (diphenylamine) (122-39-4), (15.18) ecoate, (15.19) ferylazamino (473798-59-3), (15.20) fluoroanilide (flumetover) (154025-04-4), (15.21) fluorochloromethride (flumioimide) (41205-21-4), (15.22) flusulfamide (flusulfamide) (10652-6), (15.23) tyrosol (917-304900) (3925-24-148), (15.22) sodium sulfopyrad (flunivamide) (10625-52-6), (15.23) sodium sulfoanilide (917-24) and (15.16) calcium acetate (15.16-24) fosetyl) (15.16) sodium acetate (15.16-24) and (24-24) potassium acetate (24-2) and 24-2-24-, (15.27) hexachlorobenzene (hexachlorobenzene) (118-74-1), (15.28) homdamycin (ironamycin) (81604-73-1), (15.29) methalosulfuron (methasulfocarb) (66952-49-6), (15.30) methyl isothiocyanate (556-61-6), (15.31) metrafenone (metrafenone) (220899-03-6), (15.32) milomycin (milomycin) (67527-71-3), (15.33) polymalexin (natamycin) (7681-93-8), (15.34) nickel methicone (nickel dimethenanthocarbamate) (15521-65-0), (15.35) azoxystrobin (nitrothil-isoproyl) (10552-74-6), (15.36) isophthothiazolinone (26530-20-1), (15.37) isophthora (pentachlorothiazolinone) (3437-38), (15.7-9) phenol (pentachlorothiazolinone) (3487-9-8), (15.36) isophthora cartenone (26530) isophthora cartenone (81604), (15.37-9) and (pentachlorothiazolinone (3487-9-6) salts thereof, (15.40) phenothrin, (15.41) phosphoric acid and its salts (13598-36-2), (15.42) propamocarb-foseylate, (15.43) propanosine-sodium (88498-02-6), (15.44) proquinazid (189278-12-4), (15.45) pyrimorph (868390-90-3), (15.45E) (2E) -3- (4-tert-butylphenyl) -3- (2-chloropyridin-4-yl) -1- (morpholin-4-yl) prop-2-en-1-one (1231776-28-5), (15.45Z) (2Z) -3- (4-tert-butylphenyl) -3- (2-chloropyridin-4-yl) -1- (morpholin-4-yl) prop-2-en-1-one (1231776-29) -6), (15.46) pyrrolysin (pyrolitrine) (1018-71-9) (EP-A1559320), (15.47) tebufloquin (376645-78-2), (15.48) phyllokuforam (tecloftalam) (76280-91-6), (15.49) tolnifanide (304911-98-6), (15.50) Azotoxazine (triazoxide) (72459-58-6), (15.51) trichlamide (trichlamide) (70193-21-4), (15.52) cyanamide (zaramid) (84527-51-5), (15.53) (3S,6S,7R,8R) -8-benzyl-3- [ ({3- [ (isobutyroyloxy) methoxy ] -4-methoxypyridin-2-yl } carbonyl) amino ] -6-methyl-4, 9-dioxo-1, 5-dioxolan-7-yl 2-methylpropionate (517875-34-2-34-methyl propionate (517875-34-2-34-853-5) ) (WO2003035617), (15.54)1- (4- {4- [ (5R) -5- (2, 6-difluorophenyl) -4, 5-dihydro-1, 2-oxazol-3-yl ] -1, 3-thiazol-2-yl } piperidin-1-yl) -2- [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] ethanone (1003319-79-6) (WO2008013622), (15.55)1- (4- {4- [ (5S) -5- (2, 6-difluorophenyl) -4, 5-dihydro-1, 2-oxazol-3-yl ] -1, 3-thiazol-2-yl } piperidin-1-yl) -2- [ 5-methyl-3-yl ] -piperidine -3- (trifluoromethyl) -1H-pyrazol-1-yl ] ethanone (1003319-80-9) (WO2008013622), (15.56)1- (4- {4- [5- (2, 6-difluorophenyl) -4, 5-dihydro-1, 2-oxazol-3-yl ] -1, 3-thiazol-2-yl } piperidin-1-yl) -2- [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] ethanone (1003318-67-9) (WO2008013622), (15.57)1- (4-methoxyphenoxy) -3, 3-dimethylbut-2-yl 1H-imidazole-1-carboxylate (111227-17-9), (15.58)2,3,5, 6-tetrachloro-4- (methylsulfonyl) pyridine (13108-52-6), (15.59)2, 3-dibutyl-6-chlorothieno [2,3-d ] pyrimidin-4 (3H) -one (221451-58-7), (15.60)2, 6-dimethyl-1H, 5H- [1,4] dithiino [2,3-c:5,6-c' ] dipyrrole-1, 3,5,7(2H,6H) -tetraone, (15.61)2- [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] -1- (4- {4- [ (5R) -5-phenyl-4, 5-dihydro-1, 2-oxazol-3-yl ] -1, 3-thiazol-2-yl } piperidin-1-yl) ethanone (1003316-53-7) (WO2008013622), (15.62)2- [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] -1- (4- {4- [ (5S) -5-phenyl-4, 5-dihydro-1, 2-oxazol-3-yl ] -1, 3-thiazol-2-yl } piperidin-1-yl) ethanone (1003316-54-8) (WO2008013622), (15.63)2- [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] -1- {4-, [2- [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] -1- {4- ] 4- (5-phenyl-4, 5-dihydro-1, 2-oxazol-3-yl) -1, 3-thiazol-2-yl ] piperidin-1-yl } ethanone (1003316-51-5) (WO2008013622), (15.64) 2-butoxy-6-iodo-3-propyl-4H-benzopyran-4-one, (15.65) 2-chloro-5- [ 2-chloro-1- (2, 6-difluoro-4-methoxyphenyl) -4-methyl-1H-imidazol-5-yl ] pyridine, (15.66) 2-phenylphenol and salts thereof (90-43-7), (15.67)3- (4, 5-trifluoro-3, 3-dimethyl-3, 4-dihydroisoquinolin-1-yl) quinoline (861647-85-0) (WO2005070917) (15.68)3,4, 5-trichloropyridine-2, 6-dinitrile (17824-85-0), (15.69)3- [5- (4-chlorophenyl) -2, 3-dimethyl-1, 2-oxazolidin-3-yl ] pyridine, (15.70) 3-chloro-5- (4-chlorophenyl) -4- (2, 6-difluorophenyl) -6-methylpyridazine, (15.71)4- (4-chlorophenyl) -5- (2, 6-difluorophenyl) -3, 6-dimethylpyridazine, 2-chloro-phenyl-3, 6-trichloro-dine, (15.72) 5-amino-1, 3, 4-thiadiazole-2-thiol, (15.73) 5-chloro-N '-phenyl-N' - (prop-2-yn-1-yl) thiophene-2-sulfonylhydrazide (134-31-6), (15.74) 5-fluoro-2- [ (4-fluorobenzyl) oxy ] pyrimidin-4-amine (1174376-11-4) (WO2009094442), (15.75) 5-fluoro-2- [ (4-methylbenzyl) oxy ] pyrimidin-4-amine (1174376-25-0) (WO2009094442), (15.76) 5-methyl-6-octyl [1,2,4] triazolo [1,5-a ] pyrimidin-7-amine, (15.77) Ethyl (2Z) -3-amino-2-cyano-3-phenylpropan-2-oate, (15.78) N' - (4- { [3- (4-chlorobenzyl) -1,2, 4-thiadiazol-5-yl ] oxy } -2, 5-dimethylphenyl) -N-ethyl-N-methyliminocarboxamide, (15.79) N- (4-chlorobenzyl) -3- [ 3-methoxy-4- (prop-2-yn-1-oxy) phenyl ] propionamide, (15.80) N- [ (4-chlorophenyl) (cyano) methyl ] -3- [ 3-methoxy-4- (prop-2-yn-1-oxy) phenyl ] propionamide, (15.81) N- [ (5-bromo-3-chloropyridin-2-yl) methyl ] -2, 4-dichloropyridine-3-carboxamide, (15.82) N- [1- (5-bromo-3-chloropyridin-2-yl) ethyl ] -2, 4-dichloropyridine-3-carboxamide, (15.83) N- [1- (5-bromo-3-chloropyridin-2-yl) ethyl ] -2-fluoro-4-iodopyridine-3-carboxamide, (15.84) N- { (E) - [ (cyclopropylmethoxy) imino ] [6- (difluoromethoxy) -2, 3-difluorophenyl ] methyl } -2-phenylacetamide (221201-92-9), (15.85) N- { (Z) - [ (cyclopropylmethoxy) imino ] [6- (difluoromethoxy) -2, 3-difluorophenyl ] methyl } -2-phenylacetamide (221201-92-9), (15.86) N' - {4- [ (3-tert-butyl-4-cyano-1, 2-17 thiazol-5-yl) oxy ] -2-chloro-5-methylphenyl } -N-ethyl-N-methyliminocarboxamide, (15.87) N-methyl-2- (1- { [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] acetyl } piperidin-4-yl) -N- (1,2,3, 4-tetrahydronaphthalen-1-yl) -1, 3-thiazole-4-carboxamide (922514-49-6) (WO2007014290), (15.88) N-methyl-2- (1- { [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] acetyl } piperidin-4-yl) -N- [ (1R) -1,2,3, 4-tetrahydronaphthalen-1-yl ] -1, 3-thiazole-4-carboxamide (922514-07-6) (WO2007014290), (15.89) N-methyl-2- (1- { [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] acetyl } piperidin-4-yl) -N-, [2,3, 4-tetrahydronaphthalen-1-yl ] -N-methyl-2- (1- { [ 5-methyl-3- (trifluoromethyl) -1H-pyrazol-1-yl ] acetyl } piperidin-4-yl ], [2 (1S) -1,2,3, 4-tetrahydronaphthalen-1-yl ] -1, 3-thiazole-4-carboxamide (922514-48-5) (WO2007014290), (15.90) {6- [ ({ [ (1-methyl-1H-tetrazol-5-yl) (phenyl) methylidene ] amino } oxy) methyl ] pyridin-2-yl } carbamic acid pentyl ester, (15.91) phenazine-1-carboxylic acid, (15.92) Quinolin-8-ol (134-31-6), (15.93) Quinolin-8-ol sulfate (2:1) (134-31-6) and (15.94) {6- [ ({ [ (1-methyl-1H-tetrazol-5-yl) (phenyl) methylidene ] amino } oxy) methyl ] pyridin-2-yl } carbamic acid tert-butyl ester.

(16) Other compounds, for example (16.1) 1-methyl-3- (trifluoromethyl) -N- [2' - (trifluoromethyl) biphenyl-2-yl ] -1H-pyrazole-4-carboxamide, (16.2) N- (4' -chlorobiphenyl-2-yl) -3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxamide, (16.3) N- (2',4' -dichlorobiphenyl-2-yl) -3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxamide, (16.4)3- (difluoromethyl) -1-methyl-N- [4' - (trifluoromethyl) biphenyl-2-yl ] -1H-pyrazole- 4-carboxamide, (16.5) N- (2',5' -difluorobiphenyl-2-yl) -1-methyl-3- (trifluoromethyl) -1H-pyrazole-4-carboxamide, (16.6)3- (difluoromethyl) -1-methyl-N- [4'- (prop-1-yn-1-yl) biphenyl-2-yl ] -1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.7) 5-fluoro-1, 3-dimethyl-N- [4' - (prop-1-yn-1-yl) biphenyl-2-yl ] -1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.8) 2-chloro-N- [4' - (prop-1-yn-1-yl) biphenyl-2-yl ] pyridine-3-carboxamide (known from WO2004/058723), (16.9)3- (difluoromethyl) -N- [4' - (3, 3-dimethylbut-1-yn-1-yl) biphenyl-2-yl ] -1-methyl-1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.10) N- [4' - (3, 3-dimethylbut-1-yn-1-yl) biphenyl-2-yl ] -5-fluoro-1, 3-dimethyl-1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.11)3- (difluoromethyl) -N- (4 '-ethynylbiphenyl-2-yl) -1-methyl-1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.12) N- (4' -ethynylbiphenyl-2-yl) -5-fluoro-1, 3-dimethyl-1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.13) 2-chloro-N- (4 '-ethynylbiphenyl-2-yl) pyridine-3-carboxamide (known from WO2004/058723), (16.14) 2-chloro-N- [4' - (3, 3-dimethylbut-1-yn-1-yl) biphenyl-2-yl ] pyridine-3-carboxamide (3.14) Known from WO2004/058723), (16.15)4- (difluoromethyl) -2-methyl-N- [4' - (trifluoromethyl) biphenyl-2-yl ] -1, 3-thiazole-5-carboxamide (known from WO2004/058723), (16.16) 5-fluoro-N- [4' - (3-hydroxy-3-methylbut-1-yn-1-yl) biphenyl-2-yl ] -1, 3-dimethyl-1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.17) 2-chloro-N- [4' - (3-hydroxy-3-methylbut-1-yn-1-yl) biphenyl-2-yl ] pyridine-3-carboxamide (known from WO2004/058723) Known as (16.18)3- (difluoromethyl) -N- [4' - (3-methoxy-3-methylbut-1-yn-1-yl) biphenyl-2-yl ] -1-methyl-1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.19) 5-fluoro-N- [4' - (3-methoxy-3-methylbut-1-yn-1-yl) biphenyl-2-yl ] -1, 3-dimethyl-1H-pyrazole-4-carboxamide (known from WO2004/058723), (16.20) 2-chloro-N- [4' - (3-methoxy-3-methylbut-1-yn-1-yl) biphenyl-2- Yl ] pyridine-3-carboxamide (known from WO2004/058723), (16.21) (5-bromo-2-methoxy-4-methylpyridin-3-yl) (2,3, 4-trimethoxy-6-methylphenyl) methanone (known from EP-A1559320), (16.22) N- [2- (4- { [3- (4-chlorophenyl) prop-2-yn-1-yl ] oxy } -3-methoxyphenyl) ethyl ] -N2- (methylsulfonyl) valinamide (220706-93-4), (16.23) 4-oxy-4- [ (2-phenylethyl) amino ] butyric acid and (16.24) {6- [ ({ [ (Z) - (1-methyl-1H-tetrazol-5-yl) (phenyl) methylene ] amino } oxy) Yl) methyl ] pyridin-2-yl } carbamic acid but-3-yn-1-yl ester, N- [9- (dichloromethylene) -1,2,3, 4-tetrahydro-1, 4-methylenenaphthalen-5-yl ] -3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxamide and 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid [2- (2,18184-dichlorophenyl) -2-methoxy-1-methyl-ethyl ] -amine. Where all of the mixing ingredients named under (1) to (16) can optionally form salts with suitable bases or acids if their functional groups are capable of doing so.

Bactericides which may be mentioned are: bronopol (bronopol), dichlorophen (dichlorophen), chlordine (nitrapyrin), thiram (nickel dimethysteriocurbamate), kasugamycin (kasugamycin), octhioketone (octilinone), furancarboxylic acid, oxytetracycline (oxytetracycline), probenazole (probenazole), streptomycin (streptamycin), biscumylphthalein (tecloftalam), copper sulfate and other copper preparations.

The invention has the following beneficial effects:

the composition of the phenylalkenone and the levorotatory alpha-terpineol has a synergistic effect on the hyphal growth of plant pathogenic bacteria such as cucumber target spot pathogen Corynespora cucurbitacearum (Berk. & Curt.) Wei) in a certain mass part ratio range.

Detailed Description

Reference to NYT 1156.2-2006 indoor bioassay test criteria fungicides part 2: the 6 th part of the bactericide of the experiment criterions of inhibiting the growth of pathogenic fungi hyphae and NYT 1156.6-2006 indoor bioassay of pesticides: the combined effect of the compounding was determined by evaluating the combined effect of the cyclohexenone and levorotatory α -terpineol on corynebacterium guajava (Berk. & Curt.) Wei.

According to the Sun Yunpei method, the synergistic effect of the mixed medicaments is evaluated according to the co-toxicity coefficient (CTC), namely the CTC is less than or equal to 80 and is a synergistic antagonistic effect, the CTC is less than 80 and is less than 120 and is a synergistic effect, and the CTC is more than or equal to 120. Measured virulence index (ATI) ═ EC of standard agents₅₀EC of test agent₅₀) X 100; the theoretical virulence index TTI is the virulence index of the A medicament multiplied by the percentage of the A medicament in the mixed preparation plus the virulence index of the B medicament multiplied by the percentage of the B medicament in the mixed preparation; co-toxicity coefficient (CTC) ═ mix measured virulence index (ATI)/mix theoretical virulence index (TTI)]×100。

The first embodiment is as follows:

indoor toxicity measurement of corynebacterium citrobacter (corynebacterium cassicola (Berk. & cut.) by styrofone and levo-terpineol, the test subject was collected from field cucumber target spot pathogen corynebacterium citrobacter (corynebacterium cassicola (Berk. & cut.)) Wei.).

Table 1: indoor toxicity measurements of fenapanone and levo α -terpineol against Corynebacterium cucurbitacearum (Berk. & Curt.). Wei.).

As shown in Table 1, the mixture of the cyclohexenone and the L-alpha-terpineol in the weight ratio of 1:6 has an obvious synergistic effect on Corynebacterium citrullum (Berk. & Curt.) Wei.) and has a cotoxicity coefficient of 182.83.

The invention is further illustrated by the following examples.

The field efficacy test refers to DB 37/T4105-2020 field efficacy test criterion for preventing and treating cucumber target spot by bactericides. Cucumber target spot disease grading method

Level 0: no disease spots;

level 1: the area of the lesion spots accounts for less than 5% of the area of the whole leaf;

and 3, level: the lesion area accounts for 6 to 10 percent of the whole leaf area;

and 5, stage: the lesion area accounts for 11-20% of the whole leaf area;

and 7, stage: the lesion area accounts for 21-40% of the whole leaf area;

and 9, stage: the lesion area accounts for more than 40% of the whole leaf area.

Method for calculating drug effect (treatment of sporadic incidence before application, base of unexplored)

The Colby equation is used to determine the desired effect of the mixture (Colby, S.R. Weeds1967,15,20-22. prediction of the synthetic and antibacterial responses of the biological compositions):

the following equation was used to calculate the expected value for a mixture containing two active ingredients a and B:

in the formula:

a-the observed efficacy of the active ingredient a at the same (dose) concentration used in the mixture;

b-the observed efficacy of the active ingredient B at the same (dose) concentration used for the mixture.

When the concentration (dose) of the mixture used is greater than the actual observed value (E) of the activity₀) The mixture exhibited an unexpected synergistic effect on the target.

The observed value is the prevention effect of the actually observed disease.

The field efficacy test refers to DB 37/T4105-2020 field efficacy test criterion for preventing and treating cucumber target spot by bactericides. The test site is Shandong province Shouguang city Taizhen, the time is 2020, 8, 12 days, the high temperature and the low temperature of the electrodeless end are repeated 4 times in each cell, each treatment is randomly arranged every 32 square meters, and each treatment room is provided with 1 meter of protection line.

Example two:

an aqueous emulsion of L-alpha-terpineol-hydrocinnamone.

Weighing 1.2% of levorotatory alpha-terpineol, 0.2% of hydrocinnamone, 1% of propylene glycol, 1% of fatty alcohol-polyoxyethylene ether, 2% of triphenylethylphenol polyoxyethylene ether phosphate, 3% of n-butanol and deionized water for supplementing 100%. The raw materials are uniformly mixed, and the rest of purified water is slowly added at normal temperature while stirring to obtain the homogeneous transparent microemulsion.

Weighing 1.2% of levorotatory alpha-terpineol, 1% of propylene glycol, 1% of fatty alcohol-polyoxyethylene ether, 2% of triphenylethylphenol polyoxyethylene ether phosphate, 3% of n-butyl alcohol and deionized water for supplementing 100%. The raw materials are uniformly mixed, and the rest of purified water is slowly added at normal temperature while stirring to obtain the homogeneous transparent microemulsion.

Weighing 0.2% of hydrocinnamone, 1% of propylene glycol, 1% of fatty alcohol-polyoxyethylene ether, 2% of triphenylethylphenol polyoxyethylene ether phosphate, 3% of n-butyl alcohol and deionized water for supplementing 100%. The raw materials are uniformly mixed, and the rest of purified water is slowly added at normal temperature while stirring to obtain the homogeneous transparent microemulsion.

Table 2 shows that the cucumber target spot disease is controlled by spraying at the early stage of disease attack, and the disease control effect is indicated after each treatment for 15 days after application (no safety risk is found on cucumbers, the tested cucumber variety is white jade cucumber, and the cucumber is cultivated in the open air).